Avanos Medical Stock Price, News & Analysis

Avanos Medical (NYSE:AVNS) has announced two significant leadership changes. Scott Galovan has been appointed as Senior Vice President and Chief Financial Officer, effective August 1, 2025. Galovan, who previously served as SVP of strategy and corporate development at Avanos, brings 12 years of company experience and a strong background in acquisitions and divestitures.

Additionally, CEO David Pacitti has been appointed to the company's Board of Directors, also effective August 1, 2025. In his CFO role, Galovan will oversee global finance, treasury, tax, corporate development, investor relations, accounting, and the Enterprise Program Management Office, reporting directly to Pacitti.

Avanos Medical (NYSE:AVNS) reported Q2 2025 financial results with total net sales of $175.0 million, up 1.9% year-over-year. The company posted a net loss of $76.8 million, compared to net income of $4.3 million in Q2 2024, primarily due to a $77.0 million goodwill impairment charge.

The Specialty Nutrition Systems segment showed strong performance with net sales of $102.7 million, while Pain Management & Recovery segment reached $61.0 million. The company announced the divestiture of its HA product line to Channel-Markers Medical and maintained its 2025 guidance of revenue between $665-685 million and adjusted EPS of $0.75-0.95.

Avanos Medical (NYSE:AVNS) has announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical (CMM), a private company in Raleigh, NC. The divested portfolio includes TriVisc® and GenVisc® 850 injection products for osteoarthritis knee pain treatment.

The strategic move aligns with Avanos' transformation strategy to focus on its core segments in Pain Management & Recovery and Specialty Nutrition Systems. The ownership transfer is effective immediately, with Avanos providing transition support through the end of 2025 to ensure continuity of service.

Avanos Medical (NYSE: AVNS) has scheduled a conference call to discuss its second quarter 2025 financial results on Tuesday, August 5, at 9 a.m. ET. The company will release its financial results before the market opens on the same day.

The call will be led by CEO Dave Pacitti, interim CFO Jason Pickett, and SVP of Strategy Scott Galovan. Investors can join via phone using an automatic registration link or dial in manually. A simultaneous webcast and presentation will be available through the company's investor relations website, with replay access available for one week after the call.

Avanos Medical (NYSE: AVNS) has appointed Camille Chang Gilmore as Senior Vice President and Chief Human Resources Officer. Gilmore, who previously served as Boston Scientific's global chief diversity officer and VP of HR for Interventional Cardiology, brings over 25 years of experience in building high-performing organizations. In her new role, she will oversee Avanos' people strategy, including talent acquisition, workforce planning, leadership development, and employee experience. Her extensive background includes HR leadership positions at companies like Boston Scientific, Guidant, IBM, and academic institutions. Gilmore holds a bachelor's degree in business management from Penn State and an MBA from the University of Illinois at Urbana-Champaign.

Avanos Medical (NYSE: AVNS) reported Q1 2025 financial results with total net sales of $167.5 million, up 0.8% year-over-year. The company's net income increased to $6.6 million ($0.14 per share) compared to $0.5 million ($0.01 per share) in Q1 2024. Adjusted diluted EPS rose to $0.26 from $0.22. Key segment performance: - Specialty Nutrition Systems: $101.1M in sales with 8.7% volume growth - Pain Management & Recovery: $56.2M in sales with mixed results The company maintained its 2025 revenue guidance of $665-685M but lowered adjusted EPS guidance to $0.75-0.95 due to tariff impacts. Cash position stood at $97.0M, with total debt of $107.4M as of March 31, 2025.

Avanos Medical (NYSE: AVNS) has scheduled a conference call to discuss its first quarter 2025 financial results on Tuesday, May 6 at 9 a.m. ET. The company will release its detailed results before the market opens on the same day.

The conference call will feature key leadership including CEO Dave Pacitti, interim CFO Jason Pickett, SVP of Strategy and Corporate Development Scott Galovan, and Board Chairman Gary Blackford. Participants can join via phone through an automatic registration system or through manual dialing options.

A simultaneous webcast and presentation will be available through the Investors section of Avanos Medical's website. The replay will be accessible for one week following the call.

Avanos Medical (NYSE: AVNS) announced it will take direct control of sales and distribution for its MIC-KEY enteral feeding products in the United Kingdom starting July 25, 2025. This change ends a 29-year distribution partnership with Vygon UK, who has been distributing the MIC* and MIC-KEY product family.

The strategic transition aims to strengthen Avanos' direct relationship with healthcare professionals and patients, while ensuring product availability and customer support. MIC-KEY, a low-profile feeding tube system for enteral nutrition, is currently distributed in over 60 countries across six continents and has been trusted by clinicians and patients for over 25 years.

Avanos will provide guidance to healthcare providers currently purchasing through Vygon UK to ensure a smooth transition with minimal disruption to the ordering process.

Avanos Medical (NYSE: AVNS) has appointed David Pacitti as its new Chief Executive Officer, effective April 14, 2025. Pacitti joins from Siemens Medical Solutions USA, where he served as president and Head of the Americas for Siemens Healthineers, overseeing marketing, sales, service, and support functions across North and Latin America.

Pacitti brings extensive healthcare industry experience, including leadership roles at Abbott Vascular, where he served as division vice president of U.S. commercial operations and played key roles in launching the company's first drug-eluting stent franchise. His prior experience includes positions at Guidant Corp from 1995 to 2006.

Currently, Pacitti serves as chair of AdvaMed Medical Imaging Technology Division's board and holds board positions at Orchestra BioMed and the Siemens Foundation. He holds a bachelor's degree from Villanova University and an MBA from the University of Maryland.